Flash Finance

RPG Life Sciences LimitedRPGLIFECorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 7 quarters of data
Consolidated Standalone
₹2,940.60
MCap ₹4,863 Cr · P/E 40.6
RPG Life Sciences Limited — Stock analysis & AI research RPG Life Sciences Limited — Multibagger AI analysis RPG Life Sciences Limited — Seasonality — best & worst months RPG Life Sciences Limited — Technical indicators & charts RPG Life Sciences Limited — Technical setup — score, trend, support & resistance RPG Life Sciences Limited — Live exchange announcements
📋 High ROCE Stocks📋 High Interest Coverage Stocks📋 Low Debt Stocks📋 High Promoter Holding Stocks📋 Quality + Momentum Stocks 📈 Bullish EMA Alignment📈 Volume Dry-Up Stocks📈 Multi-Timeframe Bullish Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹196 Cr
Sales · Jun 2026
+15.8% YoY
₹43 Cr
Operating Profit · Jun 2026
+22.0% YoY
22.1%
OPM % · Jun 2026
+5.2% YoY
₹31 Cr
Net Profit · Jun 2026
+17.0% YoY
₹18.60
EPS · Jun 2026
+17.0% YoY

📝 RPG Life Sciences Limited — results explained

Quarter ended June 2026 (Q1 FY27)

RPG Life Sciences Limited reported revenue of ₹196 crore for the quarter ended June 2026 (Q1 FY27), up 15.8% from ₹169 crore in the same quarter last year, and up 10.6% sequentially over the March 2026 quarter.

Net profit rose 17.0% year-on-year to ₹31 crore, from ₹26 crore. Earnings per share (EPS) came in at ₹18.60.

Operating profit stood at ₹43 crore — an operating margin (OPM) of 22.1%, compared with 21.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, RPG Life Sciences Limited posted revenue of ₹708 crore, with a net profit of ₹115 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹735 crore with a net profit of ₹120 crore.

Valuation snapshot

At the current price of ₹2,940.60, RPGLIFE has a market capitalisation of ₹4,863 crore and a trailing P/E of about 40.6.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 12th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 72.95%, foreign institutional investors (FIIs) 0.87%, domestic institutional investors (DIIs) 9.93%, public shareholders 16.25% of RPG Life Sciences Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹4,863 Cr
Current Price ?
₹2,940.6
P/E ?
40.57above ind
Industry P/E ?
37.20
P/B ?
8.04
P/S ?
6.62
P/FCF ?
-540.38
Enterprise Value ?
₹4,883 Cr
EV/EBITDA ?
31.50
PEG ?
N/A
Earnings Yield ?
2.7%
Dividend Yield ?
0.68%
Profitability & Returns
Sales (TTM) ?
₹735 Cr
OPM ?
21.1%
Profit after tax (TTM) ?
₹120 Cr
EPS (TTM) ?
₹72.49
ROCE ?
26.0%
ROE ?
19.8%
ROA ?
15.1%
Growth
Sales — latest qtr ?
₹196 Cr
PAT — latest qtr ?
₹31 Cr
YoY qtr sales growth ?
15.8%
YoY qtr profit growth ?
17.0%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹20 Cr
Debt to Equity ?
0.03
Interest Coverage ?
330.8
Current Ratio ?
N/A
Ownership
Promoter holding ?
72.95%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
2.8%
Return 6 months ?
45.2%

🗓️ Quarterly results (7 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 173143169182180177196 +15.8% +10.6%
Operating Profit 49253539403343 +22.0% +31.2%
Other Income 31155163145 -10.1% -66.4%
Interest 0000001 +384.6% —
Depreciation 5555566 +14.8% -1.7%
Profit Before Tax 471353549294041 +17.0% +3.7%
Net Profit 351172637223031 +17.0% +2.5%
EPS 21.1270.9515.9022.2813.3818.0818.60 +17.0% +2.9%
OPM % 28.3% 17.5% 21.0% 21.4% 22.1% 18.6% 22.1% +5.2% +18.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹708 Cr ₹735 Cr —
Operating Profit — ₹147 Cr ₹155 Cr —
OPM % — 20.80% 21.10% —
NPM % — 16.30% 16.32% —
Other Income — ₹39 Cr ₹38 Cr —
Depreciation — ₹22 Cr ₹22 Cr —
Interest — ₹0 Cr ₹1 Cr —
EBIT — ₹126 Cr ₹133 Cr —
PBT — ₹154 Cr ₹160 Cr —
Tax — ₹16 Cr ₹18 Cr —
Net Profit — ₹115 Cr ₹120 Cr —
EPS — ₹69.64 ₹72.34 —
Material Cost — ₹144 Cr ₹156 Cr —
Employee Cost — ₹69 Cr ₹73 Cr —
Extraordinary Items — ₹-8 Cr ₹-8 Cr —

🏛️ Balance Sheet (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
Equity Capital 1313 +0.0%
Reserves 517592 +14.5%
Borrowings 020 —
Other Liabilities 127168 +32.3%
Total Liabilities 658793 +20.5%
Fixed Assets 184200 +8.7%
CWIP 420 +400.0%
Investments 12785 -33.1%
Other Assets 343488 +42.3%
Total Assets 658793 +20.5%

💧 Cash Flow (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
Cash from Operating Activity 7856 -28.2%
Cash from Investing Activity -4286 +304.8%
Cash from Financing Activity -27-21 +22.2%
Net Cash Flow 9122 +1255.6%
Free Cash Flow 151-9 -106.0%
CFO/OP 82%64% -22.0%

➗ Ratios (latest 2 periods)

Metric Mar 2025Mar 2026 % Chg
ROCE % —26% —
Debtor Days 4860 +25.0%
Inventory Days 159179 +12.6%
Days Payable 135141 +4.4%
Cash Conversion Cycle 7299 +37.5%
Working Capital Days 115107 -7.0%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 72.95%72.95%72.95%72.95%72.95%72.95% +0.0%
FIIs 1.35%1.11%1.00%0.87%0.95%0.87% -8.4%
DIIs 6.49%6.70%7.04%7.45%8.67%9.93% +14.5%
Public 19.22%19.23%19.01%18.72%17.42%16.25% -6.7%
No. of Shareholders 25,83226,65725,90525,28223,88624,330 +1.9%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 KOPRAN Kopran ₹281.55 1,361 54.5 700 25 8.7% 3.6% -96.0% -97.6% 13.9% -10.0%
❓ Frequently asked questions
What was RPG Life Sciences Limited's revenue in Q1 FY27?
RPG Life Sciences Limited reported revenue of ₹196 crore for the quarter ended June 2026 (Q1 FY27), up 15.8% from ₹169 crore in the same quarter last year, and up 10.6% sequentially over the March 2026 quarter.
What was RPG Life Sciences Limited's net profit in Q1 FY27?
Net profit rose 17.0% year-on-year to ₹31 crore, from ₹26 crore. Earnings per share (EPS) came in at ₹18.60.
What is RPGLIFE's market capitalisation and P/E ratio?
At the current price of ₹2,940.60, RPGLIFE has a market capitalisation of ₹4,863 crore and a trailing P/E of about 40.6.
Who owns RPG Life Sciences Limited? (shareholding pattern)
As of Sep 2026, promoters held 72.95%, foreign institutional investors (FIIs) 0.87%, domestic institutional investors (DIIs) 9.93%, public shareholders 16.25% of RPG Life Sciences Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI